Seagen Inc

Overview

Seagen Inc (Seagen), formerly Seattle Genetics Inc, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas, and CD30-expressing lymphomas; and Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology, which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
Key Stats
Address
21823 30Th Drive Se, Suite, BOTHELL, Washington
Headquarters

United States of America

Contact

1 425 5274000

Website
www.seagen.com
No of Employees

2,092

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

SGEN [NASD]

Revenue (2020)

$2,176 m

137.4% (2020 vs 2019)
Net Income (2020)

$614 m

487% (2020 vs 2019)
Net Profit Margin

28 %

263% (2020 vs 2019)
Market Cap *

$27,790 m

EPS *

$3.4

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Seagen IncNovartis AGBristol-Myers Squibb CoAmgen Inc
Key Information
Headquarters United States of America Switzerland United States of America United States of America
Headquarter City BOTHELL BASEL NEW YORK THOUSAND OAKS
Headquarter State/Province Washington - New York California
No. of Employees 2,092 109,000 30,250 24,300
Entity Type Public Public Public Public

Products & Services

Seagen is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The company's product portfolio consists of:

Products
  • Marketed Adcetris (brentuximab vedotin):
  • Hodgkin lymphoma
  • CD30-expressing Peripheral T-cell lymphoma (PTCL)
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Roger D. Dansey, M.D. Chief Medical Officer Senior Management 2018 64 Mr. Roger D. Dansey has been the Chief Medical Officer of the company since 2008. Prior to this, he served...
Vaughn B. Himes, Ph.D. Chief Technical Officer Senior Management 2016 60 Mr. Vaughn B. Himes has been the Chief Technical Officer of the company since 2016. Prior to this role, he...
Todd E. Simpson Chief Financial Officer Senior Management 2005 60 Mr. Todd E. Simpson has been the Chief Financial Officer of the company since 2005. Prior to this role, he...
Clay B. Siegall, Ph.D. Chairman; Chief Executive Officer; President Executive Board 1997 60 Mr. Clay B. Siegall is the Chairman, the Chief Executive Officer and the President of the company. Prior to Seattle...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Regulatory Approval In February, the company received approval for Tukysa (tucatinib) from the European Commission for the…
2021 Contracts/Agreements In June, the company and SpringWorks Therapeutics entered into a clinical trial collaboration agreement to…
2021 Regulatory Approval In July, the company along with Astellas Pharma secured the US FDA approval for PADCEV…
2021 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Cascadian Therapeutics Inc

Address

Suite 500, 2601 4th Avenue, Seattle
United States of America

Telephone

1 206 8012100

Website

www.cascadianrx.com
Biomira Management Inc.

Address

110 110th Ave NE, Ste 550, Bellevue
United States of America

Telephone

1 425 4500370

ProlX Pharmaceuticals Corp

Address

221 East 6th Street, Tucson
United States of America

Telephone

1 520 6225552

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
09 Aug 2021 Seagen Enters into Licensing Agreement with RemeGen Licensing Agreement Seagen Inc RemeGen Co Ltd
07 Jun 2021 SpringWorks Therapeutics Enters into Clinical Collaboration with Seagen Partnership SpringWorks Therapeutics Inc; Seagen Inc
25 Mar 2021 Pieris Pharma and Seagen Enter into Clinical Trial Collaboration Partnership Seagen Inc; Pieris Pharmaceuticals Inc
24 Mar 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
12 Mar 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
14 Sep 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

7

Active Jobs

18

Posted

187

Closed

Job Trends

Latest Jobs

Job title Company Country
Senior Oncology Account Manager, Westösterreich Seagen Inc Austria
Associate Director, Corporate Communications Seagen Inc Switzerland
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar